Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $73.11

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been given an average rating of "Hold" by the twenty-one ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $73.11.

Several research firms have recently commented on CRSP. Stifel Nicolaus reduced their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Barclays raised their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Chardan Capital reduced their price objective on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, February 13th. The Goldman Sachs Group reduced their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Finally, StockNews.com raised CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th.

Remove Ads

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC increased its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the period. T. Rowe Price Investment Management Inc. increased its position in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares during the period. Capital International Investors increased its position in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after acquiring an additional 816,789 shares during the period. Baker BROS. Advisors LP increased its position in CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after acquiring an additional 743,075 shares during the period. Finally, State Street Corp increased its position in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after acquiring an additional 599,304 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock traded down $1.50 during mid-day trading on Thursday, reaching $41.99. 1,189,321 shares of the company were exchanged, compared to its average volume of 2,234,731. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $75.91. The firm's 50-day simple moving average is $43.02 and its two-hundred day simple moving average is $45.65. The firm has a market cap of $3.60 billion, a PE ratio of -9.61 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities research analysts anticipate that CRISPR Therapeutics will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.